+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dementia Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Dementia Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Dementia Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083640
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dementia Drugs Market grew from USD 10.78 billion in 2024 to USD 11.96 billion in 2025. It is expected to continue growing at a CAGR of 10.47%, reaching USD 19.60 billion by 2030.

The global burden of dementia continues to rise, imposing profound challenges on patients, caregivers, and health systems worldwide. This landscape demands innovative pharmacological interventions to manage cognitive decline, behavioral symptoms, and disease progression. As the population ages, the imperative to develop effective dementia drugs has gained urgency, spurring increased research activity and regulatory scrutiny. Recent approvals and clinical breakthroughs signal a paradigm shift, yet the market remains fragmented by drug class, administration routes, and patient demographics. This executive summary offers an authoritative overview of current treatment modalities, emerging trends, policy impacts, and actionable insights to guide decision-makers in navigating a complex, evolving environment.

Transformative Shifts Shaping the Dementia Treatment Ecosystem

Over the past decade, the dementia treatment ecosystem has undergone transformative shifts driven by scientific advances and changing care models. First, precision medicine approaches have emerged, leveraging biomarker stratification to tailor interventions. This has led to targeted therapies that address specific pathological hallmarks, such as beta-amyloid and tau protein aggregation. Second, combination regimens integrating cholinesterase inhibitors with NMDA receptor antagonists are gaining traction, optimizing symptomatic management while new disease-modifying agents advance through clinical phases. Third, digital therapeutics and artificial intelligence-powered monitoring tools are enhancing patient adherence and enabling remote titration of dosages. Collectively, these shifts underscore a transition from one-size-fits-all treatment toward highly individualized care pathways, supported by robust real-world evidence generation and adaptive clinical trial designs.

Cumulative Impact of United States Tariffs on Drug Costs and Supply Chains in 2025

In 2025, the implementation of revised United States tariffs on active pharmaceutical ingredients and finished drug products has exerted a tangible influence on cost structures and supply chain stability. Increased duties on imported raw materials have elevated production expenses, compelling manufacturers to reassess sourcing strategies and renegotiate supplier contracts. Concurrently, tariff-driven price pressures have intensified negotiations with pharmacy benefit managers and payers, leading to wider adoption of value-based pricing agreements. Meanwhile, supply chain resilience initiatives have gained prominence, as stakeholders invest in domestic manufacturing capacity and dual-source procurement to mitigate the risk of shortages. Overall, the tariff environment has underscored the importance of strategic agility, driving investments in operational excellence and cost-effective logistics solutions.

Holistic Market Segmentation Insights Across Key Dimensions

Analyzing the market through multiple segmentation lenses reveals nuanced dynamics that inform strategic positioning. When segmented by drug class, cholinesterase inhibitors-such as donepezil, galantamine, and rivastigmine-continue to dominate the symptomatic treatment space, while the memantine and donepezil combination delivers synergistic benefits in moderate cases, and NMDA receptor antagonists refine neuroprotection strategies. In terms of disease progression, patient cohorts with mild cognitive impairment show higher adoption rates of early-intervention therapies, whereas moderate and severe dementia stages demand combination and high-potency regimens. Patient type segmentation highlights early onset patients as candidates for aggressive disease-modifying trials, elderly populations requiring simplified dosing regimens, and high-risk patients benefiting from enhanced monitoring protocols. Route of administration insights reveal oral capsules, liquids, and tablets as the most prevalent formats, supported by a growing shift toward transdermal patches that improve adherence; intravenous options remain niche, reserved for acute care settings. From an end user perspective, family-led home care settings rely on user-friendly formulations and professional caregiver training, while hospitals-including general and specialized dementia clinics-prefer intravenous and immediate-release options for acute management. Mode of action analysis underscores the strategic focus on enzyme inhibitors and receptor blockers to address cholinergic deficits and excitotoxicity. Therapeutic indication segmentation shows Alzheimer’s disease as the predominant target, with Lewy body and vascular dementia niches gaining research attention. Drug formulation insights point to the importance of sustained-release technologies for stable plasma profiles. Approval status segmentation differentiates established EMA and FDA-approved therapies from promising candidates in clinical trials. Treatment duration segmentation contrasts long-term maintenance regimens against short-course interventions for symptom flare-ups. Finally, prescriber segmentation reveals neurologists and geriatricians as key influencers in therapy selection, supported by primary care providers in early-detection scenarios.

Key Regional Insights: Americas, EMEA, and Asia-Pacific Dynamics

Regional trends in the dementia drugs market vary significantly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, driven by demographic profiles, regulatory environments, and local healthcare infrastructures. In the Americas, a combination of robust reimbursement policies and advanced R&D networks accelerates uptake of novel agents, with the United States leading global clinical trial enrollment. Europe, Middle East & Africa present a heterogeneous landscape: Western European nations exhibit early adoption of value-based reimbursement models, while emerging markets in Eastern Europe and the Middle East focus on building diagnostic capacity and expanding care access. Asia-Pacific demonstrates the fastest demographic shift toward aging populations, prompting governments in Japan, South Korea, and China to subsidize dementia treatments and invest in domestic manufacturing. Cross-region partnerships and knowledge sharing are fostering harmonized clinical standards, but intellectual property considerations and localized pricing strategies remain pivotal factors in market entry and expansion.

Leading Companies and Strategic Positioning in the Dementia Drug Arena

Leading pharmaceutical and biotechnology players are strengthening their positions through targeted investments, collaborative alliances, and pipeline diversification. Anavex Life Sciences Corp. focuses on sigma-1 receptor agonists, pursuing early-phase trials for neuroprotective potential. AstraZeneca PLC leverages its global commercialization capabilities to advance combined cholinesterase and NMDA antagonist portfolios. Aurobindo Pharma Limited capitalizes on cost-effective generics manufacturing to supply key markets. Biogen Inc. drives the narrative on disease-modifying therapies with high-profile clinical programs. Eisai Co., Ltd collaborates on international studies of anti-amyloid candidates, while Eli Lilly and Company integrates immunotherapy approaches. F. Hoffmann-La Roche AG applies its diagnostic expertise to companion assays. Forest Laboratories, Inc continues to optimize dosing regimens for symptomatic relief. Janssen Global Services, LLC partners with academic centers to explore tau-targeted molecules. Merck & Co., Inc pursues strategic in-licensing to fill therapeutic gaps. Novartis AG employs precision medicine frameworks in trial design. Pfizer, Inc adopts patient-centric digital support tools. Quidel Corporation explores biomarker diagnostics. Sanofi S.A. aligns neurology and immunology research. Teva Pharmaceutical Industries Ltd. expands transdermal patch capabilities. Valeant Pharmaceuticals International, Inc focuses on emerging market expansion. Zydus Cadila strengthens its clinical pipeline for regional approvals. Collectively, these companies are shaping the competitive landscape through differentiated strategies in discovery, development, and commercialization.

Actionable Recommendations for Industry Leaders

To capitalize on evolving market opportunities, industry leaders should consider the following actionable priorities. First, integrate biomarker-driven patient stratification into clinical programs to enhance trial success rates and support premium pricing. Second, invest in modular manufacturing platforms and dual-sourcing arrangements to safeguard supply continuity amid tariff and geopolitical uncertainties. Third, form cross-sector partnerships with digital health innovators to develop adherence monitoring and telemedicine solutions that complement pharmacotherapy. Fourth, engage with payers and policymakers early to design outcomes-based contracts that align reimbursement with real-world effectiveness. Fifth, tailor market access strategies to regional regulatory nuances, leveraging local clinical data and health-economic evidence. By aligning R&D priorities with operational resilience and strategic collaborations, stakeholders can drive sustainable competitive advantage in the dementia drugs market.

Conclusion: Positioning for the Next Phase of Growth

As the dementia drugs market enters its next growth phase, stakeholders must balance innovation with accessibility, ensuring that cutting-edge therapies reach the patients who need them most. The convergence of precision medicine, advanced delivery systems, and digital health underscores a holistic approach to dementia care. Regulatory agencies and payers are increasingly receptive to adaptive trial designs and value-based reimbursement, creating fertile ground for breakthrough products. Meanwhile, demographic trends and global policy initiatives are expanding patient populations and elevating the importance of equitable access. By maintaining a proactive stance on scientific innovation, supply chain resilience, and stakeholder engagement, organizations can navigate complexities and contribute to meaningful improvements in cognitive health outcomes.

Market Segmentation & Coverage

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Cholinesterase Inhibitors
    • Donepezil
    • Galantamine
    • Rivastigmine
  • Combination Drugs
    • Memantine And Donepezil Combination
  • NMDA Receptor Antagonists
    • Memantine
  • Mild Cognitive Impairment
  • Moderate Dementia
  • Severe Dementia
  • Early Onset Patients
  • Elderly Patients
  • High-Risk Patients
  • Intravenous Administration
  • Oral Administration
    • Capsules
    • Liquid Form
    • Tablets
  • Transdermal Administration
    • Patches
  • Home Care Settings
    • Family Care
    • Professional Care
  • Hospitals
    • General Hospitals
    • Specialized Dementia Clinics
  • Enzyme Inhibitors
  • Receptor Blockers
  • Alzheimer’s Disease
  • Lewy Body Dementia
  • Vascular Dementia
  • Immediate Release
  • Sustained Release
  • EMA Approved
  • FDA Approved
  • In Clinical Trials
  • Long-Term Treatment
  • Short-Term Treatment
  • Geriatricians
  • Neurologists
  • Primary Care Providers

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dementia Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Anavex Life Sciences Corp.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forest Laboratories, Inc.
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Quidel Corporation
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Zydus Cadila

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dementia Drugs Market, by Drug Class
8.1. Introduction
8.2. Cholinesterase Inhibitors
8.2.1. Donepezil
8.2.2. Galantamine
8.2.3. Rivastigmine
8.3. Combination Drugs
8.3.1. Memantine And Donepezil Combination
8.4. NMDA Receptor Antagonists
8.4.1. Memantine
9. Dementia Drugs Market, by Stage Of Dementia
9.1. Introduction
9.2. Mild Cognitive Impairment
9.3. Moderate Dementia
9.4. Severe Dementia
10. Dementia Drugs Market, by Patient Type
10.1. Introduction
10.2. Early Onset Patients
10.3. Elderly Patients
10.4. High-Risk Patients
11. Dementia Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous Administration
11.3. Oral Administration
11.3.1. Capsules
11.3.2. Liquid Form
11.3.3. Tablets
11.4. Transdermal Administration
11.4.1. Patches
12. Dementia Drugs Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.2.1. Family Care
12.2.2. Professional Care
12.3. Hospitals
12.3.1. General Hospitals
12.3.2. Specialized Dementia Clinics
13. Dementia Drugs Market, by Mode Of Action
13.1. Introduction
13.2. Enzyme Inhibitors
13.3. Receptor Blockers
14. Dementia Drugs Market, by Therapeutic Indication
14.1. Introduction
14.2. Alzheimer’s Disease
14.3. Lewy Body Dementia
14.4. Vascular Dementia
15. Dementia Drugs Market, by Drug Formulation
15.1. Introduction
15.2. Immediate Release
15.3. Sustained Release
16. Dementia Drugs Market, by Approval Status
16.1. Introduction
16.2. EMA Approved
16.3. FDA Approved
16.4. In Clinical Trials
17. Dementia Drugs Market, by Treatment Duration
17.1. Introduction
17.2. Long-Term Treatment
17.3. Short-Term Treatment
18. Dementia Drugs Market, by Prescriber
18.1. Introduction
18.2. Geriatricians
18.3. Neurologists
18.4. Primary Care Providers
19. Americas Dementia Drugs Market
19.1. Introduction
19.2. Argentina
19.3. Brazil
19.4. Canada
19.5. Mexico
19.6. United States
20. Asia-Pacific Dementia Drugs Market
20.1. Introduction
20.2. Australia
20.3. China
20.4. India
20.5. Indonesia
20.6. Japan
20.7. Malaysia
20.8. Philippines
20.9. Singapore
20.10. South Korea
20.11. Taiwan
20.12. Thailand
20.13. Vietnam
21. Europe, Middle East & Africa Dementia Drugs Market
21.1. Introduction
21.2. Denmark
21.3. Egypt
21.4. Finland
21.5. France
21.6. Germany
21.7. Israel
21.8. Italy
21.9. Netherlands
21.10. Nigeria
21.11. Norway
21.12. Poland
21.13. Qatar
21.14. Russia
21.15. Saudi Arabia
21.16. South Africa
21.17. Spain
21.18. Sweden
21.19. Switzerland
21.20. Turkey
21.21. United Arab Emirates
21.22. United Kingdom
22. Competitive Landscape
22.1. Market Share Analysis, 2024
22.2. FPNV Positioning Matrix, 2024
22.3. Competitive Analysis
22.3.1. Anavex Life Sciences Corp.
22.3.2. AstraZeneca PLC
22.3.3. Aurobindo Pharma Limited
22.3.4. Biogen Inc.
22.3.5. Eisai Co., Ltd
22.3.6. Eli Lilly and Company
22.3.7. F. Hoffmann-La Roche AG
22.3.8. Forest Laboratories, Inc.
22.3.9. Janssen Global Services, LLC
22.3.10. Merck & Co., Inc.
22.3.11. Novartis AG
22.3.12. Pfizer, Inc.
22.3.13. Quidel Corporation
22.3.14. Sanofi S.A.
22.3.15. Teva Pharmaceutical Industries Ltd.
22.3.16. Valeant Pharmaceuticals International, Inc.
22.3.17. Zydus Cadila
23. ResearchAI
24. ResearchStatistics
25. ResearchContacts
26. ResearchArticles
27. Appendix
List of Figures
FIGURE 1. DEMENTIA DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DEMENTIA DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DEMENTIA DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2024 VS 2030 (%)
FIGURE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 32. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 38. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MEMANTINE AND DONEPEZIL COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY EARLY ONSET PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ELDERLY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HIGH-RISK PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY FAMILY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PROFESSIONAL CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALIZED DEMENTIA CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LEWY BODY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY EMA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY FDA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY IN CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SHORT-TERM TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GERIATRICIANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NEUROLOGISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PRIMARY CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 121. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. CANADA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. CANADA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 124. CANADA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 125. CANADA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 126. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. CANADA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. CANADA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. CANADA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. CANADA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. CANADA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 132. CANADA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. CANADA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. CANADA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 135. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 136. CANADA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 137. CANADA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 138. CANADA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 144. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. MEXICO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. MEXICO DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. MEXICO DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. MEXICO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. MEXICO DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. MEXICO DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 153. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 154. MEXICO DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 156. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 213. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. CHINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. CHINA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 216. CHINA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 217. CHINA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 218. CHINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. CHINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. CHINA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. CHINA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. CHINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. CHINA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 224. CHINA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. CHINA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 226. CHINA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 227. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 228. CHINA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 229. CHINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 230. CHINA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 231. INDIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. INDIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. INDIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 234. INDIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 235. INDIA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 236. INDIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. INDIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. INDIA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. INDIA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. INDIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. INDIA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 242. INDIA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 243. INDIA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. INDIA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 245. INDIA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 246. INDIA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 247. INDIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 248. INDIA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 267. JAPAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. JAPAN DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. JAPAN DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 270. JAPAN DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 271. JAPAN DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 272. JAPAN DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. JAPAN DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. JAPAN DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. JAPAN DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. JAPAN DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. JAPAN DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 278. JAPAN DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 279. JAPAN DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. JAPAN DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 281. JAPAN DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 282. JAPAN DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 283. JAPAN DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 284. JAPAN DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 318. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 319. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 320. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 324. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 325. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 326. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 327. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 332. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 333. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 334. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
TABLE 335. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
TABLE 336. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 337. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 338. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY PRESCRIBER, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY STAGE OF DEMENTIA, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA DEMENTIA

Companies Mentioned

  • Anavex Life Sciences Corp.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forest Laboratories, Inc.
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Quidel Corporation
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Zydus Cadila

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dementia Treatment Market Size, Share & Trends Analysis Report by Indication, Drug Class, Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Dementia Treatment Market Size, Share & Trends Analysis Report by Indication, Drug Class, Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Lewy Body Dementia Treatment Market by Drug Type, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Lewy Body Dementia Treatment Market by Drug Type, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Dementia Treatment - Global Strategic Business Report - Product Image

Dementia Treatment - Global Strategic Business Report

  • Report
  • 204 Pages
  • Global
From
Dementia Drugs Market by Indications, Drug Class - Global Forecast 2025-2030 - Product Image

Dementia Drugs Market by Indications, Drug Class - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2025-2033 - Product Image

Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From

About the Dementia Drug Market

The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators. Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.